Studies have shown that these blood-based biomarkers can differentiate between AD and healthy controls, predict the progression from mild cognitive impairment (MCI) to AD and correlate with amyloid and tau pathology in the brain [9,10]. The gene discussed is MAPT; the disease is Alzheimer disease.